Navigation Links
New Clinical Endocrinology Guidelines Support Lp-PLA2 Measurement For Risk Assessment of Coronary Artery Disease
Date:4/26/2012

SOUTH SAN FRANCISCO, Calif., April 26, 2012 /PRNewswire/ -- diaDexus, Inc. (OTC Bulletin Board: DDXS), a company focused on the development and commercialization of proprietary cardiovascular diagnostic products, today announced the inclusion of its vascular-specific inflammatory marker Lp-PLA2 in the American Association of Clinical Endocrinologists ("AACE") medical guidelines for clinical practice published in the March/April 2012 issue of Endocrine Practice.

"The AACE's guidelines are an important endorsement of the clinical utility of Lp-PLA2 measurement. Specifically, the guidelines recommend the use of multiple markers, including Lp-PLA2, to assist physicians in personalizing ther­apy for elevations or other abnormalities in blood lipids. These abnormalities, commonly referred to as "dyslipidemia," are a major risk factor for coronary artery disease," said Brian E. Ward, Ph.D., Chief Executive Officer of diaDexus.  "As more health care professionals utilize Lp-PLA2 as a component of cardiovascular risk assessment, we believe that diaDexus' PLAC Test for Lp-PLA2 should contribute to saving lives."

The AACE is the third major association of medical professionals to underscore the value of Lp-PLA2. The new recommendations complement medical guidelines published by the American College of Cardiology Foundation/America Heart Association and the American Stroke Association, in 2010 and 2011.  These two earlier guidelines support Lp-PLA2 measurement for assessment of cardiovascular risk in asymptomatic adults and for primary prevention of stroke.

The new AACE guidelines(1) recommend Lp-PLA2 measurement as part of global risk assessment for patients with dyslipidemia, and have identified elevated Lp-PLA2 levels as an important risk factor for the development of vascular disease. Dyslipidemia i
'/>"/>

SOURCE diaDexus, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Varian Medical Systems and Siemens Healthcare Announce Global Collaboration to Advance Clinical Capabilities and Offerings in Radiotherapy and Radiosurgery
2. Southern Research Signs Agreement with Apath, LLC to Conduct Preclinical Studies with Virus-Based HCV Screenings
3. AtheroNova Signs Agreement for Development of Clinical Trial Supplies
4. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
5. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
6. Clinical Trial at Evergreen Healthcare Shows Intestinal Gel Reduces Symptoms of Advanced Parkinsons Disease
7. Webcast Alert: Isis Pharmaceuticals Holds Webcast to Discuss Clinical Development Plans for ISIS-APOCIIIRx
8. Global BioClinical Launches New Website
9. Frost & Sullivan: Industry Push toward Quantitative Imaging Positions Computer Aided Detection and Diagnosis Adequately for Renewed Clinical Expansion
10. R&D Trends: Depression - Clinical attrition driven by mature market conditions
11. New Studies Demonstrate Clinical Utility and Validity of CancerType ID® Molecular Classifier
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Oct. 22, 2014  Regulus Therapeutics Inc. ... company leading the discovery and development of ... it has demonstrated human proof-of-concept with a ... evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting ... C virus infection ("HCV").  Interim results from ...
(Date:10/20/2014)...  Indianapolis interventional medical device maker NICO ... 3D visualization leader Synaptive Medical announced ... Meeting that they have joined forces to integrate ... is the first of its kind and will ... NICO,s BrainPath® interventional access technology and Synaptive,s BrightMatter™ ...
(Date:10/20/2014)... --  BioNano Genomics announced today achievement of a major ... data at 30X depth, sufficient for a genome map, in ... established and demonstrated for the IrysChip TM V2, the ... and will be rolled out to BioNano,s collaborators and customers ... advancement at the American Society for Human Genetics (ASHG) ...
Breaking Medicine Technology:A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 2Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 3Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 4Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 5BioNano Genomics Announces One Human : One Chip : One Day 2BioNano Genomics Announces One Human : One Chip : One Day 3
... Arno Therapeutics, Inc., a clinical-stage biopharmaceutical company focused ... Food and Drug Administration ("FDA") accepted the Company,s ... of AR-12, a potentially first-in-class, orally available, PDK1 ... the endoplasmic reticulum stress pathway. Acceptance of ...
... ValueOptions(R), Inc., the nation,s largest ... support for the use of The Joint Commission,s ... basis for the recently completed pilot program was ... to help patients receive the most appropriate and ...
Cached Medicine Technology:FDA Accepts Arno Therapeutics' IND for AR-12 a PDK1 Inhibitor That Blocks the PI3K/Akt Pathway 2FDA Accepts Arno Therapeutics' IND for AR-12 a PDK1 Inhibitor That Blocks the PI3K/Akt Pathway 3ValueOptions(R) Supports New Hospital-Based Performance Measures to Help Patients Get the Best Treatment for Inpatient and Outpatient Services 2
(Date:10/22/2014)... 22, 2014 For Dr. Iris Hunter, a ... it’s an extension of her life’s mission. Her extensive experience ... the owner of FirstLight HomeCare, make it clear that Hunter’s ... me that my work makes a difference in the lives ... spirit, so after much research, I felt ready to start ...
(Date:10/22/2014)... Hay House is pleased to announce the official ... Life (Paperback; $10.82) written by the highly esteemed Tommy Rosen, ... book is meant to help readers of all kinds end ... , Recovery 2.0 is not the average self-help book, or ... guide for what comes next. For many, Alcoholics ...
(Date:10/22/2014)... Losing Weight Your Body’s Way , In a ... the face, it certainly can be difficult to choose the ... extra favor by doing it the healthy way? Set aside ... to your body, exercise regularly, and choose foods with the ... weight; you need to exercise more and eat less. Despite ...
(Date:10/22/2014)... Steven Reinberg HealthDay Reporter ... who quickly add weight and length may be showing a ... In adults, certain genes have been linked to increased ... gains in fat and lean muscle, the researchers said. ... and taller. By ages 2 and 3, however, these genes ...
(Date:10/22/2014)... 21, 2014 (HealthDay News) -- Measures taken by Firestone ... Ebola-ravaged Liberia may have limited the spread of the ... The Firestone Natural Rubber Co. provides health services ... of nearby densely populated communities. Between Aug. 1 ... Ebola cases among those 80,000 people. That incidence rate ...
Breaking Medicine News(10 mins):Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2
... Health Research (CIHR) announced its latest awards for injury ... two of them were headed by doctors at St. ... a team studying traumatic brain injuries (TBI). Researchers working ... will examine rural Canadians, access to trauma centres. ...
... available in Spanish . The incidence ... time. The phenomenon brings with it the possibility of neurological, ... in the short and the medium term. These consequences also ... is currently known that the progress of a premature baby ...
... about making errors, according to a new study published ... Association for Psychological Science. The researchers measured brain waves ... mistakes on a test. Those who had been prepared ... mistakes than those who hadn,t. "Eighty-five percent of ...
... Reporter , TUESDAY, Aug. 3 (HealthDay News) -- Stroke patients ... may not be protected from second strokes or heart ... association between homocysteine, an amino acid, in the blood, and ... supplements lower homocysteine levels, but whether this really has an ...
... a model that will enable them to investigate, for the ... they are in the womb. Until now it has been ... this discovery will enable researchers to understand the processes that ... (TGCC) in young adult life, and how factors, such as ...
... Gardner HealthDay Reporter , TUESDAY, Aug. 3 (HealthDay ... to an emergency room with a violent injury and who ... new research finds. The authors calculated that for every ... violent episode in the future. The study was funded ...
Cached Medicine News:Health News:St. Michael's receives prestigious grants to study trauma 2Health News:Mothers of premature children run greater risk of suffering stress 2Health News:Brain study shows that thinking about God reduces distress -- but only for believers 2Health News:Vitamin B May Not Guard Against Second Stroke, Heart Attack 2Health News:Vitamin B May Not Guard Against Second Stroke, Heart Attack 3Health News:Scientists develop the first model for investigating the origins of testicular cancer in humans 2Health News:One Therapy Session in ER Can Cut Teen Violence 2Health News:One Therapy Session in ER Can Cut Teen Violence 3
... Open heart surgery is no longer ... septal defects in young children and in ... care providers are seeking non-surgical options to ... Occluder is a permanently implanted prosthesis and ...
... Network (NLTN) is a training system sponsored ... (APHL) and the Centers for Disease Control ... in a variety of formats and offers ... Library. Log on to www.nltn.org for a ...
... Testing and Quality Assurance (for Waived and ... POLs, clinics and small hospitals maintain laboratory ... of patient lab results and assist labs ... opportunity to earn 12 P.A.C.E. Contact hours ...
An indirect immunofluorescence (IFA) antibody test for the detection and semiquantitation of anti-glomerular basement membrane (GBM) antibodies in human serum. Slide Detail: 6-well Monkey Kidney Subs...
Medicine Products: